This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: National Institute of Health and Medical Research, Assistance Publique-Hopitaux De Paris, Université Paris Diderot-Paris 7. Active years: 2012-2021.
Location History:
- Romainville, FR (2012)
- Paris, FR (2021)
Company Filing History:
2 out of 1,853 
1 out of 331 
1 out of 111 
Years Active: 2012-2021
Title: The Innovative Mind of Olivier Clermont: Pioneering Bacteriophage Research
Introduction: Olivier Clermont, an accomplished inventor based in Paris, France, has made significant contributions to the field of bacteriophage research. With two patents to his name, Clermont is dedicated to tackling the growing challenge of antibiotic resistance through innovative solutions.
Latest Patents: One of Clermont's latest patents is focused on a bacteriophage strain capable of producing a lytic infection in the ST131-025b:H4 clone. This invention addresses the rising burden of the ST131-025b:H4 clonal complex, known for its prevalence in human community and hospital-acquired infections. The bacteriophage LM33_P1 demonstrates an impressive 100% specificity for 025b strains and offers 70% coverage for the major antibiotic-resistant pandemic clonal complexes ST131-025b:H4 and ST69-025b. His research evaluated the in vivo activity of LM33_P1, revealing its ability to infect bacteria across various organs. This innovative bacteriophage includes a polypeptide corresponding to the bacteriophage tail fiber protein, crucial for its attachment to the ST131-025b:H4 clone.
Career Highlights: Throughout his career, Olivier Clermont has worked with prominent research institutions, including the Institut National de la Santé et de la Recherche Médicale and Assistance Publique—Hôpitaux de Paris. His work has focused on addressing public health issues associated with bacterial infections, particularly those caused by antibiotic-resistant strains.
Collaborations: Clermont has collaborated with notable professionals in the field, including Erick Denamur and Tony Le Gall. Their combined expertise has advanced research efforts aimed at understanding and combating antibiotic resistance in bacterial infections.
Conclusion: Olivier Clermont's dedication to innovative bacteriophage research and his contributions through patented inventions highlight the importance of finding alternative solutions to antibiotic resistance. As the challenges in healthcare continue to evolve, inventors like Clermont play a vital role in paving the way for future advancements in medical treatment.